Publications by authors named "Kitty Moores"

Claim this Profile
S
Strategies for In Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense Drugs.
Piotr J Kamola, Klio Maratou, Paul A Wilson, Kay Rush, Tanya Mullaney, Kitty Moores

Mol Ther Nucleic Acids· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization.
Piotr J Kamola, Jeremy D A Kitson, Gemma Turner, Klio Maratou, Sofie Eriksson, Kitty Moores

Nucleic Acids Res· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological Characterization of a Novel ENaCα siRNA (GSK2225745) With Potential for the Treatment of Cystic Fibrosis.
Kenneth L Clark, Stephen A Hughes, Pallav Bulsara, Jill Coates, Kitty Moores

Mol Ther Nucleic Acids· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo activity of an azole series of CCR2 antagonists.
Chris A Smethurst, Nicola Bevan, Carl Brooks, Amanda Emmons, Peter J Gough, Kitty Moores

Bioorg Med Chem Lett· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a sulfonamide series of CCR2 antagonists.
Simon Peace, Joanne Philp, Carl Brooks, Val Piercy, Kitty Moores

Bioorg Med Chem Lett· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach.
Theo A Berkhout, Frank E Blaney, Angela M Bridges, David G Cooper, Ian T Forbes, Kitty E Moores

J Med Chem· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.
Josie A Blackie, Jackie C Bloomer, Murray J B Brown, Hung Yuan Cheng, Beverley Hammond, Kitty E Moores

Bioorg Med Chem Lett· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.
Josie A Blackie, Jackie C Bloomer, Murray J B Brown, Hung-Yuan Cheng, Richard L Elliott, Kitty E Moores

Bioorg Med Chem Lett· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity.
Andreas Ludwig, Theo Berkhout, Kitty Moores, Pieter Groot, Gayle Chapman

J Immunol· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PPARgamma is not a critical mediator of primary monocyte differentiation or foam cell formation.
Lisa Patel, Steven J Charlton, Ian C Marshall, Gary B T Moore, Phil Coxon, Kitty Moores

Biochem Biophys Res Commun· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis